Lv51
990 积分 2023-05-06 加入
Bispecific nanobodies – promising engineered candidates with high therapeutic efficiency
7小时前
已完结
Migraine
21天前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
1个月前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
2个月前
已完结
Efficacy and safety of GW117 tablets in major depressive disorder: a randomised, double-blind, placebo-controlled, phase 2 dose-finding study
2个月前
已关闭
ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies
2个月前
已完结
Chronic Kidney Disease
4个月前
已关闭
Chronic Kidney Disease
4个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
4个月前
已完结
In vivo CAR-Ts captivate big pharma
5个月前
已完结
皖公网安备34019202002308
